In the same patient subgroup as the FALCON trial (postmenopausal HR+ advanced breast cancer), patients in MONALEESA2 who received ribociclib, a CDK4/6 inhibitor, experienced a 44% improvement in PFS, meeting its primary end point early. Here, CDK4 is linked to breast cancer.